1. The Regulatory Framework

AAMI TIR57:2016 (Principles for medical device security, Risk management) was issued by the Association for the Advancement of Medical Instrumentation as a Technical Information Report developed jointly with the U.S. FDA. Although a TIR is informative rather than a normative standard, FDA premarket cybersecurity guidance, most recently the September 2023 final guidance "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions", incorporates TIR57's risk-management approach by reference and treats conformance as evidence of an adequate Secure Product Development Framework (SPDF) under 21 U.S.C. 360n-2 (added by the Consolidated Appropriations Act of 2023, Section 524B).

TIR57 covers any medical device meeting the FD&C Act definition that contains software, firmware, or programmable logic, or that is itself a Software-as-a-Medical-Device (SaMD). Scope includes Class I, II, and III devices, with intensified expectation for Class II/III devices that are network-connected, contain a cyber-physical interface to the patient, or process electronic Protected Health Information under HIPAA. Manufacturers are the primary covered entity; healthcare delivery organizations and device integrators inherit derivative obligations through procurement and joint security plans.

Section 524B, effective March 29, 2023, made FDA cybersecurity content mandatory for premarket submissions of "cyber devices." Failure to provide an SPDF, a Software Bill of Materials (SBOM), and a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities is now a Refuse-to-Accept (RTA) ground under 21 CFR 814.42 and the parallel 510(k) acceptance criteria. Enforcement is administered by the Center for Devices and Radiological Health (CDRH), and noncompliance can produce warning letters, import alerts, consent decrees under 21 U.S.C. 332, and product seizure under 21 U.S.C. 334. TIR57 conformance is the de facto evidentiary path manufacturers use to satisfy the SPDF prong.

TIR57 itself is structured around ISO 14971-style risk management, but adapted to security: it requires identification of assets, threats, vulnerabilities, and exploits; evaluation of cybersecurity risk in terms of exploitability and impact (rather than ISO 14971's probability of harm); and risk-control selection. A 2027 revision (TIR57 R2) under AAMI Working Group SM/WG01 expands postmarket surveillance, SBOM continuity, and coordinated vulnerability disclosure obligations.

2. The Architectural Requirement

Read structurally rather than procedurally, TIR57 requires three architectural properties that no amount of process documentation can substitute for. First, devices must support continuous, attributable evidence of integrity: the device's running firmware, configuration, and security posture must be observable to the manufacturer's postmarket surveillance system in a way that distinguishes a genuine device from a counterfeit, and an authentic firmware image from a tampered one.

Second, every security-relevant event, boot, configuration change, credential use, anomaly detection, vulnerability disclosure correlation, must be recorded in a tamper-evident log that preserves attribution across the device's clinical lifetime. TIR57 §5.4 (Risk Control) and §6 (Production and Post-Production Activities) presume the existence of such evidence; without it, "verification of risk-control effectiveness" reduces to a paperwork artifact.

Third, devices must support cryptographically anchored identity that survives software re-imaging and that cannot be cloned by an adversary with possession of a sister device. This is the architectural meaning of FDA's "trustworthy device" criterion in §IV.A of the 2023 premarket guidance, and it is what TIR57's identification, authentication, and authorization controls (mapped from IEC TR 80001-2-2 capabilities ALOF, AUTH, NAUT, PAUT) require at the substrate level.

Together, these three properties, attested integrity, tamper-evident lineage, and unclonable identity, form an architectural primitive. They are not features that can be added to an existing device by patching the application layer; they require silicon-anchored or protected-execution-anchored mechanisms designed in from the outset. TIR57's process clauses are downstream consumers of this primitive; they cannot synthesize it.

3. Why Procedural and Bolt-On Compliance Fails

The dominant compliance pattern in medical-device cybersecurity treats TIR57 as a documentation exercise: a Cybersecurity Risk Management Plan, a threat model document, a vulnerability-management SOP, and a postmarket monitoring procedure. The artifacts pass FDA acceptance review and survive routine inspection. They do not, however, prevent the failure modes TIR57 is designed to address.

The structural mismatch is that procedural compliance produces evidence about the manufacturer's processes, not about the deployed device's state. When a hospital network reports that a clinically-deployed infusion pump is exhibiting anomalous behavior, the canonical TIR57 §6.4 postmarket scenario: the manufacturer holds documents describing how it would investigate, but lacks attested telemetry sufficient to distinguish firmware tampering, supply-chain implant, counterfeit substitution, or benign hardware fault. Recall decisions therefore default to fleet-wide conservatism, multiplying cost and clinical disruption.

Bolt-on telemetry agents do not solve this. An agent running on the device's main application processor shares the threat surface with the workload it is monitoring; an attacker who can modify firmware can equally modify the agent's reports. TIR57 §5.4.3 control verification requires evidence that the controls are effective in the threatened state, which application-layer telemetry cannot provide. The substrate problem is non-substitutable.

4. What the Health-Monitoring Primitive Provides

The health-monitoring substrate disclosed in U.S. Provisional Application No. 64/049,409 is an architectural primitive comprising three structurally interlocked elements. The first is device-integrity and supply-chain provenance attestation. At manufacture time the device is provisioned with a device-specific keypair generated inside a tamper-resistant storage element such that the private half is never exposed outside that boundary; the public half, together with manufacturer, manufacture-lot, and hardware-revision identifiers and a cryptographic hash of the firmware at manufacture, is signed by a manufacturer authority and recorded as a manufacture-attestation governed observation in a credentialing-authority registry. In deployment, a device-authenticity attestation evaluator, a firmware-integrity chain monitor that tracks updates through the authorized-update-authority chain, a tamper-evident seal monitor, and a software-bill-of-materials attestation verifier continuously produce governance-credentialed observations of authenticity status (continuously-valid, expired, revoked, or never-attested). These observations are evaluated against policy, so a remote authority within the credentialed taxonomy (manufacturer, regulator, healthcare delivery organization) can distinguish an authentic device running authentic firmware from a tampered, counterfeit, or supply-chain-implanted one without relying on uncredentialed telemetry and without revealing patient data.

The second element is tamper-evident governance-chain lineage. Every health-relevant event, each observation, assessment, aggregation, fault localization, degradation response, service event, credential operation, and authority-reporting event, is recorded in a governance-chain lineage field bound to the device's credentialed identity. The lineage recorder supports deterministic reconstruction of the recorded history, so that an attacker with firmware control cannot retroactively rewrite the record without producing a detectable discontinuity, and the resulting evidence is attributable to a specific authority rather than pooled as anonymous platform logs. This is the substrate that TIR57 §5.4.4 control monitoring and §6.4 postmarket surveillance presume.

The third element is continuity-based device identity hardened by PUF-response monitoring. Device identity is established not by a static serial number or PKI enrollment alone but through a dynamic device hash carried on every governed observation, whose sequence encodes identity continuity; spoofing and replay are detected as discontinuities in that sequence even when the spoofing device possesses a valid-looking credential. A physical-unclonable-function challenge-response monitor, observing per-die silicon variation that is unique and resistant to characterization, supplies governance-credentialed observations of PUF-response consistency that bind the continuity sequence to the specific physical die. The combination produces an identity that resists cloning by flash extraction, resists counterfeit-silicon spoofing, and cannot be silently transferred when a device is decommissioned, salvaged, or returned for service.

The element-by-element mapping to TIR57 is direct. TIR57 §4.3 (asset identification) requires a device inventory; the continuity-based, PUF-hardened identity provides cryptographically authoritative per-device identity. TIR57 §5.3 (threat analysis) requires consideration of firmware-substitution, supply-chain-implant, and counterfeit threats; the device-authenticity and firmware-integrity attestation makes these threats observable rather than speculative. TIR57 §5.4 (risk controls) requires controls effective in the threatened state; the substrate's hardware-protected boundary places the attestation and lineage outside the application-layer threat surface. TIR57 §6 (postmarket) requires continuing assurance; the lineage stream provides continuing evidence, not periodic snapshots.

5. Compliance Mapping: TIR57 Clauses to Architectural Elements

TIR57 §4.2 (Scope of risk management) maps to the substrate's per-device identity boundary: the unit of risk management is the attested device instance, not the SKU. TIR57 §4.3 (Information for risk management) maps to the lineage stream: the substrate continually supplies the inputs that §4.3 requires the manufacturer to have. TIR57 §5.2 (Risk analysis, Identification of vulnerabilities) maps to firmware-integrity and SBOM-attestation observations bound to the credentialed device identity, which make vulnerability presence in deployed devices empirically determinable against actual installed configurations rather than nominal ones.

TIR57 §5.3 (Risk evaluation) maps to attested-state-conditional risk scoring: the substrate distinguishes a device in a known-good state from a device in an indeterminate or attested-bad state, allowing risk evaluation to be conditioned on actual rather than assumed state. TIR57 §5.4 (Risk control, implementation, verification, residual evaluation) maps to the substrate's hardware-protected control boundary, which provides verifiable separation between the controls and the threat surface.

TIR57 §6.2 (Information collection) and §6.3 (Information review) map to the lineage anchoring and evidential weighting layer, which produces attributable, time-anchored evidence rather than aggregated process logs. TIR57 §6.4 (Actions) maps to graduated response keyed to attestation outcome: a device that fails attestation can be quarantined at the network or clinical-workflow boundary without recalling the fleet. FDA Section 524B's SBOM and postmarket-monitoring obligations map to the lineage structure's ability to record SBOM-component provenance per attested instance and to surface vulnerability matches against deployed configurations rather than nominal ones.

6. Adoption Pathway

The deploying entity is the medical-device manufacturer, with downstream conformance benefits flowing to healthcare delivery organizations and Group Purchasing Organizations who can require attested-substrate devices in procurement. The transition path begins with new platform programs, where the silicon-anchored substrate can be specified into the bill of materials at design freeze; retrofit into existing platforms is constrained by hardware roots of trust and is generally feasible only at major refresh cycles.

For Class II 510(k) devices, the substrate enters the premarket submission as the SPDF foundation under FDA's 2023 guidance, with TIR57 conformance reported against the architectural elements rather than against process artifacts. For Class III PMA devices, the substrate becomes part of the device design history file and supports the Section 524B postmarket-monitoring plan. For SaMD distributed across heterogeneous host hardware, the substrate's attestation primitive maps onto whatever hardware-attested secure enclave or host-platform hardware root of trust the host exposes, with the lineage and identity layers operating above.

At the fleet level, the per-device observations aggregate into governance-credentialed fleet-health indicators (availability rate, mean-time-between-failures, degradation trends, and cascade-risk indicators) with failure-prediction forecasting and predictive-maintenance projection, so a manufacturer or healthcare delivery organization can reason about an entire deployed fleet from attributable evidence rather than from periodic, uncredentialed check-ins.

The freedom-to-operate posture established by this dated, public disclosure is that an attested medical-device cybersecurity substrate built from credentialed device-integrity and supply-chain provenance attestation, tamper-evident governance-chain lineage, and continuity-based PUF-hardened identity, evaluated against policy and aggregated into fleet health, is disclosed here as an enabling implementation of the Health Monitoring inventive step of U.S. Provisional Application No. 64/049,409. The disclosure is intended to put the field on notice and to support broad claim coverage of the substrate as TIR57 R2 and Section 524B enforcement converge on the structural property.

7. Disclosure Scope

The technology underlying this application, namely the governed fleet health-monitoring substrate (continuity-based device identity and the dynamic device hash, per-device integrity and supply-chain provenance attestation, PUF-response consistency monitoring, tamper-evident governance-chain lineage, and policy-evaluated fleet health aggregation), is disclosed in U.S. Provisional Application No. 64/049,409. The AAMI TIR57, FDA Section 524B, and connected-medical-device deployment framing in this article is an application of that disclosed technology and is provided to establish enabling, dated, public notice; it does not enlarge the technical disclosure beyond U.S. Provisional Application No. 64/049,409.